Calvin Sandra
Known title: VP, Corp Controller and CAOCIK: 0001882909
Associated companies
Transaction History
| TVTX | ▼ Sell | Open Market | 4,275 | $266K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 800 | $50K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 300 | $19K | 9/15/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 2,500 | $69K | 9/15/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 1,250 | $28K | 9/15/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 1,625 | $33K | 9/15/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 2,500 | $56K | 4/14/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 6,250 | $56K | 4/14/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 6,500 | $133K | 4/14/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 21,977 | $903K | 4/14/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 4,333 | $139K | 2/3/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 15,180 | $0 | 1/31/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 7,402 | $296K | 12/24/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,910 | $105K | 12/15/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 10,000 | $253K | 11/4/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 17,500 | $470K | 11/4/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 15,000 | $413K | 11/4/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 12,500 | $280K | 11/4/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 6,250 | $56K | 11/4/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 67,115 | $2.4M | 11/4/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 10,000 | $162K | 2/11/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 10,000 | $250K | 2/11/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 10,000 | $174K | 2/11/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 10,000 | $250K | 2/11/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 15,000 | $232K | 2/11/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 15,000 | $375K | 2/11/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 9,244 | $231K | 2/11/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 10,000 | $180K | 2/11/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 10,000 | $250K | 2/11/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 3,348 | $67K | 2/3/2025 | View on chart |
| TVTX | ▲ Buy | Grant | 13,000 | $0 | 1/31/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 925 | $18K | 1/22/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 15,000 | $190K | 12/26/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 15,000 | $258K | 12/26/2024 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 15,000 | $190K | 11/25/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 12,090 | $221K | 11/25/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,820 | $24K | 2/1/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 12,500 | $0 | 1/31/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 1,000 | $0 | 1/31/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 910 | $8K | 1/23/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 122 | $2K | 5/11/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 436 | $7K | 5/10/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 360 | $8K | 2/2/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,671 | $36K | 2/1/2023 | View on chart |
| TVTX | ▲ Buy | Grant | 10,000 | $0 | 1/31/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 192 | $4K | 1/25/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 905 | $20K | 1/24/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 349 | $10K | 9/13/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 445 | $10K | 5/11/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 436 | $9K | 5/10/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 798 | $21K | 1/31/2022 | View on chart |
| TVTX | ▲ Buy | Grant | 8,750 | $0 | 1/31/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 934 | $23K | 1/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data
Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.